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Abstract: 
Unmatched allogeneic in utero stem cell transplantation (IUSCT) produces poor 
engraftment unless the fetus has congenital immunodeficiency, probably because of 
maternal and fetal immune responses to injected cells. We studied the functional 
haematopoietic potential of transduced GFP+ sheep AF stem cells, before and after 
autologous IUSCT. CD34+ cells were selected from first trimester sheep AF, 
transduced overnight and injected intravenously into NOD-SCID-gamma (NSG) mice. 
At 3 months primary recipient bone marrow (BM) was injected into secondary NSG 
recipients. GFP+ cells were detected in the haematopoietic organs and peripheral 
blood of primary and secondary recipients at 3 months. Autologous IUSCT 
(transduced GFP+CD34+AF) was performed in fetal sheep. Six months postnatally, 
lamb BM was injected into secondary NSG recipients. GFP+ cells were detected in 
the peripheral blood of primary and secondary recipients. This confirms the 
haematopoietic potential of AF stem cells supporting the concept of autologous 
IUSCT to treat congenital haematopoietic disease.  
 
Keywords: sheep CD34, amniotic fluid stem cells, autologous transplantation, cell 
therapy.
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Introduction 
In utero stem cell transplantation (IUSCT) aims to provide the fetus with 
therapeutic cells for to correct prenatal congenital diseases. Beside the obvious 
advantage of preventing the development of pathology in utero and thus avoiding 
postnatal complications, intervening during fetal life has a stoichiometric advantage, 
allowing the transplantation of much larger cell doses on a per kilogram basis than 
can be achieved postnatally [1]. Finally, the maturation of the immune system during 
the fetal life allows new antigens to be introduced early in gestation without rejection, 
and can induce immunologic tolerance to these new antigens [2].   
Despite all the above, results of allogeneic IUSCT [3] in humans have been 
successful only for the treatment of congenital severe combined immunodeficiency 
(SCID) [4]. Allogeneic mesenchymal stem cells (MSCs) injected into fetuses affected 
with osteogenesis imperfecta successfully engrafted in only 2 out of 5 cases [4]. 
Attempts to treat other diseases such as sickle cell disease [5] or metabolic storage 
disorders for example, have been unsuccessful.  
In the last few years work conducted by Flake and colleagues [6] has 
demonstrated that this may be at least partially explained by the migration of the in 
utero injected cells into the maternal circulation and mounting of a rejection response, 
which could diminish the engraftment. This is most likely due in mice to activated 
maternal T cells which can cross the placenta in mice and destroy engrafted 
allogeneic cells [7]. In order to avoid this response, stem cells matched to the fetus 
or even the mother could be used. Fetal mice injected with congenic haematopoietic 
stem cells (HSCs) for example, all maintained stable, long-term, multilineage 
chimerism compared with fewer than 20% of allogeneic recipients [8].  
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Alternatively, in monogenic disease, stem cells derived from the fetus itself 
could be used after genetic modification for treatment of a fetus affected by a 
congenital disease. Fetal stem cells can be easily derived during pregnancy from the 
amniotic fluid (AF) [9-11]. In particular, ckit+ amniotic fluid stem cells (AFSC) are 
characterized by long-term self-renewal, clonal properties and differentiation 
capabilities which defined them at a pre-pluripotent status [9, 12, 13]. They share 
with embryonic stem cells the expression of some stem markers (e.g. OCT4 and 
SSEA4), but they are not tumorigenic unless reprogrammed as induced pluripotent 
stem cells (iPS) [14].  
Using a sheep model we have previously shown the potential of transduced 
AF mesenchymal stem cells (AFMSCs) for autologous IUSCT [15]. After first 
trimester amniocentesis, AFMSCs could be isolated, cultured, transduced and 
transplanted back into the donor fetus as an in utero autologous transplant. 
Engraftment of GFP transduced cells was detected two weeks after transplantation 
in various tissues and organs.   
In this study we hypothesised that cells with haematopoietic potential were 
also present in sheep AF and could be used for autologous IUSCT. We used a 
recently developed novel sheep-specific CD34 antibody that identifies 
haematopoietic stem cells in the adult sheep bone marrow [16]. After selecting 
CD34+ cells from the AF, we transplanted them into NOD-SCID-gamma (NSG) 
immunocompromised mice to study their engraftment, and into donor fetal sheep 
after gene marking them using a viral vector for autologous IUSCT. For the first time, 
we have demonstrated that AF-derived cells from a large animal (sheep) possess 
haematopoietic potential in xenotransplanted mice, and can mediate long-term 
engraftment after autologous IUSCT in the sheep. 
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Methods 
All procedures on animals were conducted in accordance with UK Home 
Office regulations and Guidance for the Operation of Animals (Scientific Procedures) 
Act (1986). 
Sheep animal procedures 
Time-mated Romney breed ewes were used. Eight fetuses from four ewes provided 
first trimester amniotic fluid (AF, 300-700 ml, 60 to 64 days of gestation) that was 
collected at post mortem examination under sterile conditions and frozen, for later 
use in transplantation experiments into NSG mice. Ten fetuses from five ewes were 
used for in utero autologous transplantation experiments. Here, general anesthesia 
was induced with Ketamine (4mg/kg, Merial, UK) intravenously, and after intubation, 
the ewes were maintained on Isoflu ane-Vet 3% (Merial, UK) in oxygen. Fetal 
measurements were confirmed by ultrasound [17]. The first procedure, ultrasound-
guided amniocentesis, was performed in the first trimester (60 - 64 days of gestation, 
term = 145 days) using a 22 Gauge, 15cm echo-tip needle (Cook Medical, USA). 
Amniotic fluid (AF, 10ml) was withdrawn from each amniotic sac.  Two days later 
ewes were re-anaesthetized as above for the second procedure, an ultrasound-
guided intraperitoneal injection of freshly isolated and transduced CD34+ amniotic 
fluid stem (AFS) cells (2x104, 1-2ml) into the donor fetus using a 22-gauge 15cm 
echo-tip disposable needle (Cook Medical, USA). To ensure correct needle 
placement within the peritoneal cavity, the needle was inserted through the anterior 
abdominal wall of the fetal sheep superior and lateral to the fetal bladder to avoid the 
umbilical arteries. Microbubbles observed moving within the peritoneal cavity as the 
cells were instilled confirmed correct needle placement.  Following recovery of the 
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ewe, fetal wellbeing and standard measurements of growth (occipital snout length, 
biparietal diameter, femur length and abdominal circumference) were measured 
every 20 days until birth [17]. 
At birth, lambs were weighed and measured (girth at umbilicus, biparietal 
diameter, standing height to shoulder) and assessed for wellbeing (time to standing, 
heart rate, respiratory rate, temperature, and oxygen saturation). Lambs were fed 
naturally with ewe breast milk. Lamb peripheral blood was collected from the jugular 
vein (No. 18 needles with 20ml syringe) at birth and every 2 weeks thereafter for flow 
cytometry analysis. Data on lamb growth and wellbeing were collected regularly until 
scheduled post mortem examination at 6 months of age. This was performed under 
general anesthesia to allow sterile collection of lamb bone marrow (BM) from 
multiple sites (sternum, femur, humerus and iliac crest) using a trocar needle, and 
sampling from all internal organs. Ewes underwent a scheduled post mortem 
examination with extensive tissue sampling at 3 months after birth once weaning 
was completed.  
Isolation and characterization of sheep CD34+ AFS cells and adult BM cells  
Fresh sheep CD34+AFS cells were selected using a sheep-specific primary 
monoclonal IgG1 CD34 antibody [16] immediately after fluid collection using MACS 
system (Miltenyi Biotec, Germany). The primary CD34 antibody was incubated with 
sheep AF total cells for 15 minutes on ice (1:100 concentration). After washing out 
the primary antibody, the secondary antibody (rat anti-mouse IgG1 MicroBeads, 
Miltenyi Biotec, Germany) was incubated with the previous cell suspension for15 
minutes on ice (1:100 concentration). Before sorting, the MS columns were rinsed 
with PBS with 0.5% BSA. The CD34+ fraction of cells conjugated with microbeads 
was collected after washing three times with PBS. Adult sheep BM collected from the 
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sternum was washed by passing through a cell strainer with PBS, and CD34+ cells 
were selected as described above for AFS. Sheep CD34+AFS or BM cells were 
prepared as single cell suspensions in PBS and counted. Fresh unsorted sheep AF 
cells were frozen down in FBS (90%) and DMSO (10%) in liquid nitrogen for 3 to 6 
months before NSG mice transplantation experiments and thawed for CD34+ sorting 
and transplantation. Sorted CD34+ cells were characterized using sheep-specific 
surface antibodies including FITC or PE conjugated CD14, CD31, CD44, CD58, 
CD34, and CD45 (AbD Serotec, UK) by flow cytometry.  
Culture and viral transduction of sheep CD34+AFS or BM cells 
Frozen CD34+AFS or BM cells were used immediately after thawing. The cell 
suspension was centrifuged at 1500rpm for 5 minutes, the supernatant was 
discarded and the thawed cells were resuspended in culture medium for viral 
transduction. Fresh or thawed CD34+AFS or thawed CD34+BM cells were 
transduced for 48 hours with a lentivector encoding the HIV-1 central polypurine tract 
element, the Spleen Focus Forming Virus LTR promoter, and the marker gene eGFP, 
at MOI=50 as previously describe [15]. The culture medium contained basal IMEM, 
10% FBS, and StemSpan CC100, which contains a combination of cytokines 
including Flt-3, Stem cell factor (SCF), IL3, and IL6 (Stemcell Technologies, UK). 
Fresh or frozen CD34+ AFS or frozen CD34+BM cells (1x105) were seeded in 24-
well low attachment plates with culture medium for 48 hours (370C, 5% CO2). The 
lentivector (10ul, MOI=50) was added while seeding the cells into each well. After 48 
hours of viral transduction, the cell suspension was washed and re-suspended in 
PBS for in utero autologous injection or NSG mice injection.  
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Xenotransplantation of NOD-SCID gamma mice and collection of peripheral blood 
and organs 
NSG mice, up to 12 weeks of age, were sublethally irradiated (3Gy) 1 hour 
prior to xenotransplantation. Sheep fresh or frozen CD34+AFS cells, or adult 
CD34+BM cells (3x105 in 0.2ml PBS using 0.5ml insulin syringe with 27½ gauge 
needle) (BD, UK) were injected into the tail vein of primary or secondary NSG mice.  
At four and eight weeks after transplantation, NSG recipients were sedated 
using vaporised Isoflurane-Vet 5% in oxygen (VetTech Solutions Ltd, UK), and the 
peripheral blood was sampled from an incision on the tail made using a scalpel (No. 
11 blade). Blood (100ul) was collected by pipette into a heparin-rinsed 
microcentrifuge tube. Red blood cells (RBC) lysis solution (1ml, 5-PRIME Inc, USA) 
was added to each blood sample for 5 minutes at room temperature. The sample 
was centrifuged (1500 rpm for 5 minutes), the supernatant was removed, and the 
procedure was repeated with RBC lysis solution until the pellet was clean. The pellet 
was resuspended in 300µl PBS for flow cytometry analysis of GFP+ cells.  
At 12 weeks of age, all recipient mice were sedated (vaporised Isoflurane-Vet 
5% in oxygen, VetTech Solutions Ltd, UK), and blood (0.5 to 1ml) was collected via 
intracardiac puncture using a 22 gauge needle. The mice were sacrificed by manual 
dislocation of cervical cord and underwent extensive post mortem examination and 
tissue harvest (liver, thymus, heart, striated muscle from thigh, lung, kidney, spleen, 
adrenal gland and gonad). Femoral bones were collected for retrieval of bone 
marrow. Liver and spleen samples were ground using a syringe plunger in a sterile 
dish, rinsed with PBS, then filtered through a cell strainer (40µm nylon mesh, BD, 
UK). The BM was flushed from the femoral bones with PBS using a 22 gauge needle 
with syringe and then strained. RBC lysis buffer (2ml) was added to each sample for 
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10 minutes at room temperature and then centrifuged (1500 rpm for 5 minutes). The 
supernatant was removed, the pellet was suspended in 300µl PBS, and washed and 
centrifuged again. The supernatant was discarded and the pellet was resuspended 
in 300µl PBS at 4°C for flow cytometry. 
Flow cytometry for eGFP detection and analysis 
Single cell suspensions of fetal or lamb spleen, liver and BM were prepared 
immediately following animal sacrifice by straining tissue through a 40µm cell 
strainer. After rinsing with PBS, red-blood cell lysis buffer was added for 5 minutes at 
37°C. Mononuclear cells were isolated from the umbilical cord and maternal blood 
samples by density gradient centrifugation using Ficoll-Paque solution (Stem Cell 
Technology, Canada). Single cell suspensions from control uninjected ewes and 
their fetuses were used as negative controls for sheep samples. Uninjected CD1 
mice were used as the negative control for mice experiments. The cells were 
acquired on Becton Dickinson FACSCalibur and LSR II machines (Becton Dickinson, 
San Jose, CA), and analyzed using FlowJo version 5.7.1 software (Tree Star, USA). 
Ten thousand events were collected per sample. 
eGFP+ signal was detected using FITC gating in all the organs of NSG mice, 
sheep and lambs. The organs from YFP+ mice were used as a positive control. To 
study transduction efficiency, the same FITC channel was used to gate the eGFP+ 
population, untransduced AFS cells were used as negative control, and AFS cells of 
YFP transgenic mice were used for the positive control.  
PCR for detection of eGFP DNA 
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PCR to detect eGFP DNA was performed as previously described (Shaw et al, 
2011). DNA from sheep AFS cells transduced with eGFP was used as a positive 
control.   
Colony forming unit (CFU) assay  
MethoCult® GF H4434 kit and M3434 kit (Stem Cell Technologies, Canada) 
were used to perform CFU assays for sheep CD34+AFS or BM cells and NSG mice 
BM cells. CD34+ cells that were isolated by MACS were added into methylcellulose 
cocktail containing cytokines and growth factors (1x104 cells per plate). The mixture 
was vortexed and plated into sterile 35mm plates that were then incubated for 14 
days (37°C, 5% CO2 in humidified atmosphere). Colonies were then scored using an 
inverted microscope and colony forming unit-granulocyte, erythrocyte, monocyte, 
megakaryocyte (CFU-GEMM), colony forming unit-granulocyte, monocyte (CFU-
G/M/GM) and burst-forming unit/CFU-erythroid (BFU/CFU-eE) were recorded. 
Confocal microscopy 
Fresh sheep and mouse tissues, embedded in OCT, were snap frozen in 
methyl-butane and liquid nitrogen and were cut into 10-15µm sections using a 
cryostat (OTF, Bright, UK). Blocking solution was prepared with 1% BSA, 0.15% 
Glycine and 0.1% Triton in PBS and preserved at 4oC. The liver sample slides were 
co-stained with mouse monoclonal anti-GFP antibody (A11120, Invitrogen, UK) and 
rabbit polyclonal anti-alpha fetoprotein (AFP) antibody (ab74663, abcam, UK) at 
1:100 dilution with buffer solution. Slides were incubated for 2 hours at room 
temperature. The secondary antibodies, Alexa Fluor 488 goat anti-rabbit IgG and 
Alexa Flour 594 donkey anti-mouse IgG (A11008 and A21203, Invitrogen, UK) were 
used (1:100 dilution) for another two hours incubation at room temperature. The 
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sample slides were observed using confocal microscopy (Leica TCS SP5 II, 
Germany), and the images were analyzed with the software ImageJ (NIH, US). The 
green positive signal indicated the eGFP+ cells, and the red signal indicated 
hepatocytes staining with AFP.  
 
Results 
Sheep CD34+ AF cells and CD34 BM cells both have haematopoietic potential 
Amniotic fluid (mean volume 487ml, range 300-700ml) collected from first 
trimester time mated sheep (n=8, mean gestational age 62 days, range 60-64) at 
post mortem examination show d a mean total cell count of 6.25 x106 (range 6-
8x106 cells), with a similar percentage of CD34+ cells for fresh (n=4) and frozen (n=4) 
AF samples (Figure 2A). The percentage of CD34+ cells from adult sheep BM was 
also similar to that in the AF (Figure 2A, 2B). CD34+ cells derived from fresh or 
frozen AF, and from BM were seeded into semi-solid culture in vitro and generated 
haematopoietic colonies with a similar percentage of CFU-GEMM, CFU-G/M/GM 
and BFU/CFU-E (Figure 2C, 2D). Both AF and BM derived CD34+ cells were 
positive for CD45 (96.5%, 95.1%, and 94.3% in fresh AF, frozen AF, and adult BM 
groups, respectively), but were negative for MSC markers including CD44 and CD58 
(Figure 2E). Moreover, the cells were also homogenously negative for CD14 
(monocyte marker) and CD31 (endothelial cell marker; Figure 2E).  
Sheep CD34+ AF cells are effectively transduced with lentiviral vectors 
Following selection of sheep CD34+ cells using MACS, cells from all three 
sources were transferred into ultra-low attachment 24-well plates at a seeding 
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density of 100000 cells/ml, and grown with conditioned? medium containing 
cytokines. Cells were transduced with a lentivector (HIV-SFFV vector encoding 
eGFP, 1x109/ml, MOI=50) for 48 hours before transplantation. Mean transduction 
efficiency tested 72 hours after incubation using flow cytometry was 56.63% ± SD 
11.0% (range 46.9 -73.2%, n=6, Figure 2F).  There was no significant difference in 
transduction efficiency of cells between the three cell sources. 
 
Transduced sheep eGFP+ CD34+ cells engraft haematopoietic organs in NSG mice 
The experimental design is shown in Figure 1. For primary xenogeneic 
transplantation, sheep CD34+ containing eGFP+ and eGFP- cells from three 
sources (3x105 cells of fresh AF, frozen AF, and adult BM) were injected into NSG 
mice (n=14; fresh AF n=4, frozen AF n=6, adult BM n=4).  Two mice that received 
injection of frozen AF cells died within 10 days due to poor tolerance to irradiation; 
the other animals survived long-term until sch duled post-mortem examination (12 
out of 14, 85.7% survival). Blood samples collected from all primary transplanted 
NSG mice at 1 and 3 months were analysed using flow cytometry.  Blood from YFP 
transgenic mice was used as a positive control, while blood from an uninjected NSG 
mouse was the negative control. eGFP+ cells were detected in the peripheral blood 
at 1 month after primary xenogeneic transplantation of sheep CD34+eGFP+ frozen 
AF, fresh AF, or adult BM cells (mean eGFP+ cells: 3.24%, 3.48%, and 4.9%, 
respectively) and at 3 months (mean eGFP+ cells: 3.12%, 3.4%, and 5.26%, 
respectively Figure 3A). There was a higher percentage of eGFP+ cells detected in 
the peripheral blood of NSG mice injected with sheep adult BM CD34+ cells 
compared to sheep CD34+ cells from AF sources at 3 months (p<0.05, ANOVA). 
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There was no significant difference in the percentage of eGFP+ cells in NSG mice 
injected with frozen or fresh sheep AF CD34+ cells. At sacrifice, eGFP+ cells were 
detectable in the BM of all animals transplanted with frozen AF, fresh AF, and adult 
BM cell sources, with no significant differences detected (n=3 per group, mean 
eGFP+ cells; 12.03%, 14.87%, and 15.87%, respectively, Figure 3B). After culture in 
semi-solid conditions, the number of eGFP+ colonies per high power field was 
significantly higher in BM cells of NSG mice that received transduced sheep CD34+ 
adult BM cells compared to those injected with transduced CD34+ sheep frozen, but 
not fresh, AF cells (p<0.05 Figure 3C). Besides blood and BM, eGFP DNA was 
detected by PCR in the liver (8 out of 9 transplanted NSG mice), spleen (5 out of 9), 
and the adrenal gland (2 out of 9; Figure 4A). There was no signal detectable in 
tissue samples from the heart, muscle, lung, kidney, thymus and gonad. PCR results 
were confirmed by FACS, and showed eGFP+ cells in the spleen and liver at 3 
months after injection (Figure 4B and C). Transplantation of transduced sheep 
CD34+eGFP+ adult BM cells resulted in a slighter higher engraftment rate than cells 
from fresh AF and frozen AF sources, in the spleen (6.7%, 5.8%, and 5.2%), and in 
liver (15.6%, 14.3%, and 8.5%, Figure 4B), but this difference did not reach 
significance. Only in the liver, did NSG mice that received frozen AF cells show a 
significantly lower engraftment than the other two groups (p<0.05, ANOVA; Figure 
4C). Immunofluorescence study showed the presence of eGFP+ cells in liver 
samples of all transplanted NSG mice, that were cuboid in shape, consistent with 
hepatocyte morphology (Figure 4D). Co-staining with alpha fetoprotein (AFP, Figure 
4E) showed a few double-stained cells providing further evidence of hepatocyte 
differentiation. The percentage of eGFP+ cells per high power field in liver samples 
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was not significantly different among the three cell sources (1.2% to 1.8%) (Figure 
4F).  
Secondary transplantation into NSG mice 
Secondary NSG mice were transplanted with BM cells collected from femoral bones 
of primary NSG mice recipients transplanted with frozen (n=3) and fresh (n=3) AF, 
and adult BM (n=2) CD34+ cells at 3 months time (Figure 2). Freshly isolated BM 
cells (3x106 per recipient) were injected into the tail vein of secondary NSG 
recipients. As for primary transplantation, these mice were treated with a sub-lethal 
dose of irradiation one hour before transplantation. Survival to scheduled post-
mortem examination at three months was 100%. At one month after transplantation, 
eGFP+ cells could be detected in the peripheral blood of 6 out of 8 secondary 
transplanted animals (2 out of 3 frozen AF, 2 out of 3 fresh AF, and 2 out of 2 adult 
BM group, Figure 5A). There was a significantly higher level of engraftment in the 
peripheral blood of secondary NSG recipients that were transplanted with the BM 
from transduced sheep CD34+eGFP+ BM cell injected NSG primary recipients 
compared with frozen AF and fresh AF groups. The percentage of eGFP+ cells in the 
peripheral blood of secondary transplanted mice was around 2 to 4%, and these 
levels were maintained up to the scheduled post-mortem examination at 3 months 
post-transplantation (Figure 5B).  Flow cytometric analysis of other haematopoietic 
organs three months after transplantation showed the presence of eGFP+ cells in 
the liver, spleen, and BM of the secondary NSG recipients that also had eGFP+ cells 
in the peripheral blood. Animals exhibiting no eGFP+ cells in their peripheral blood 
also showed no engraftment in liver, spleen and BM. There were no eGFP+ cells 
detected in the thymus of any animals at three months after transplantation (Figure 
5B).   
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In utero autologous transplantation with sheep CD34+ AFS cells  
Time-mated pregnant ewes (n=5, 10 twin fetuses) were studied (Figure 1). 
The overall survival to live-birth after the operative procedure was 50% (5 out of 10). 
In one twin pregnancy, both fetuses miscarried within a week of the amniocentesis 
procedure. In another twin pregnancy, both fetuses had reduced fetal growth velocity 
around 100 days and were found to have died in utero at 126 days of gestation. 
Bacterial cultures of endometrium showed evidence of endometritis with a coliform. 
In a second twin pregnancy, one twin demised at 90 days of gestation, but the other 
continued to term and was born healthy. Fetal growth velocity was normal in all 
cases that survived to birth. Five lambs of three ewes were delivered at term. All 
lambs had normal initial assessments at birth (time to stand, heart rate, respiratory 
rate, O2 saturation and temperature) and birthweights were within the normal range. 
In each of the born twin pairs, one twin lamb was rejected by the ewe and both 
lambs became dehydrated within 24 hours of birth. One ewe had obvious mastitis, 
but the other ewe did not. Despite artificial feeding, the lambs’ condition deteriorated 
and an elective post-mortem examination was performed two days after birth on the 
advice of the veterinary surgeons. There was no evidence of structural abnormality 
or infection at post-mortem examination of these lambs. The remaining three lambs 
grew at a normal rate, and survived to scheduled post-mortem examination at 6 
months of age.  
Long-term engraftment in lambs after in utero autologous transplantation  
eGFP+ cells were detected in the peripheral blood of all lambs that survived to 
birth (mean = 2.72%, range 1.6% to 4.5%, Figure 6B). In those lambs that survived 
long-term, the peripheral blood remained eGFP+ up to scheduled post-mortem 
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examination at 6 months of age (M1-A, M2-B, and M3-A, Figure 6B). The strength of 
the eGFP+ signal started to decrease after 4 weeks of age (4 months after in utero 
injection), but the level of eGFP+ cells in the blood remained steady at around 2% up 
to 6 months of age.  Samples of haematopoietic organs were collected from lambs at 
birth (n=2) and eGFP+ cells were detected by flow cytometry in the liver (2.9%, 4.3%) 
and the BM (2.2%, 2.5%). The spleen and thymus were negative for eGFP+ cell 
engraftment in both lambs.  At 6 months of age, BM was collected from the surviving 
lambs (n=3) from multiple sites (femur, humerus, iliac crest and sternum) under 
terminal anaesthesia as part of the scheduled post-mortem examination. eGFP+ 
cells were detected in the BM (mean = 4.05%, range 2.43 to 5.47%, Figure 7A), and 
also in the peripheral blood and liver (data not shown). 
 
Secondary xenogeneic transplantation of AF-derived sheep haematopoietic-
repopulating cells into NSG recipient mice  
In order to further confirm the haematopoietic potential of CD34+ AF cells, 
whole unfractionated BM isolated from the transplanted lambs was transplanted into 
NSG secondary recipient mice (3X105 cells, n=9, with BM from one lamb being 
transplanted into three NSG recipients) with 100% survival to scheduled post-
mortem examination at three months post-transplantation. eGFP+ cells could be 
detected in the peripheral blood at 1, 2, and 3 months after secondary 
transplantation (2 out of 9 mice). At three months after secondary transplantation, 
eGFP+ cells were detected by flow cytometry in the liver, blood, and BM of 
secondary NSG recipient mice (Figure 7B, 7C). PCR analysis of haematopoietic 
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tissues also demonstrated eGFP+ DNA in the liver, blood, BM, spleen and thymus 
(Figure 7C). 
  
Discussion  
In this study we have demonstrated that CD34+ cells can be isolated from 
sheep amniotic fluid, transduced, and reconstitute haematopoiesis in primary and 
secondary NSG recipient mice, with evidence of engraftment in multiple 
haematopoietic organs.  In addition, autologous IUSCT of these cells into donor 
sheep fetuses results in long-term engraftment in the peripheral blood and 
haematopoietic organs up to the last sampling time of 6 months after birth (9 months 
post-IUSCT). Finally, transduced cells derived from those animals maintained their in 
vivo haematopoietic potential and showed haematopoietic engraftment when 
transplanted into NSG recipients.  
Our results showed that CD34+ cells isolated from sheep AF and BM possess 
a similar haematopoietic potential. AF and BM sheep cells isolated using a novel 
sheep-specific CD34 antibody were also positive for CD45, but negative for CD31, 
CD14, CD44, CD58, a haematopoietic phenotype which is in keeping with their 
potential to form colonies, further proving that the presence of cells in the AF with 
haematopoietic potential is not limited to mice and humans [13]. After being 
transduced, cells were transplanted without sorting for two reasons. Firstly, we 
focused on maximising cell number since the efficiency of gene transfer achieved in 
the CD34+ sheep AF or BM cells was relatively high at around 60%. This is higher 
that what has been previously reported in human bone marrow-derived MSC, HSC, 
and embryonic stem cells, in which gene transfer efficiency was 40% [18], 50% [19], 
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and 14-48% [20], respectively. We have previously shown that human AFS cells can 
be efficiently transduced using adenoviral vectors [21], and we achieved a similar 
transduction efficiency using a lentivector in sheep AF-derived MSCs [15]. 
Lentivectors also have the advantage of allowing sustained transgenic protein 
expression [22]. Secondly, we wished to avoid clonal selection of the cells and rather 
to observe what could happen with minimal cell manipulation.  
After primary transplantation into NSG recipients, the haematopoietic potential 
of these cells was demonstrated using flow cytometry, PCR, and immunostaining, 
which confirmed that these cells engrafted in most of the haematopoietic organs. 
CD34+ BM cells tended to have a slightly higher rate of engraftment compared to 
CD34+ cells derived from frozen AF, but a similar rate to cells derived from fresh AF. 
This is in keeping with the finding that haematopoietic stem cells could be more 
sensitive to cryopreservation, as described before for other cell sources such as 
peripheral blood stem cells [23]. 
 Having demonstrated their haematopoietic potential in NSG mice, we tested 
whether AF-derived CD34+ stem cells could engraft following autologous IUSCT in 
sheep. Transduced autologous cells readily migrated from the peritoneal cavity 
injection site to engraft all of the major haematopoietic organs, providing continued 
transgenic protein (eGFP) expression in multiple fetal organs, the BM, and the 
peripheral blood. Tissue analysis by PCR, immunofluorescence, and flow cytometry 
revealed that CD34+ AF or BM cells preferentially engrafted, as expected, in the fetal 
liver and other haematopoietic organs [24]. Admittedly, the level of tissue 
engraftment was low, which is likely due to the small number of autologous cells 
transplanted. For some congenital diseases however, such as severe haemophilia 
for example, only 1% level of protein expression is required to ameliorate the severe 
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phenotype [25].  Thus, for many congenital diseases the levels of engraftment we 
achieved may be sufficient to improve the phenotype or even effect a cure. 
Increasing the number of cells delivered is likely to lead to improved levels of 
engraftment.  Currently however, expansion of AF stem cells results in the 
production of committed MSC progenitors, and expansion while maintaining 
haematopoietic progenitors has not yet been achieved. Other options for increasing 
the level of engraftment rate could include targeting the liver with direct injection, 
resulting in a degree of liver damage that could potentially enhance liver engraftment. 
Indeed, prior work demonstrated that intrahepatic injection of human MSC into first 
trimester fetal sheep gave a higher level of engraftment (12.5%), particularly in the 
parenchyma, when compared with intraperitoneal injection (2.6%), which resulted in 
higher periportal generation of hepatocytes [26]. A combined injection approach 
might therefore result in the highest level and broadest distribution of donor-derived 
hepatocytes. In current clinical practice, however, intraperitoneal injection is the 
route of choice for fetal transfusion in the first trimester, due to its inherent safety, but 
improvements in fetal imaging may make first trimester intravascular injection more 
feasible. Damaging an organ such as the liver or muscle provides a proliferation 
stimulus for the transplanted stem cells and may create a donor stem cell advantage 
for engraftment. For example, protocols such as postnatal boosting after irradiation, 
donor lymphocyte infusion [27, 28] or co-transplantation of MHC-matched purified 
facilitating cells [29] have been used successfully in the fetal mouse to improve 
engraftment.  
A limitation of this study was the lack of data on the fetal and maternal 
immune response, since we were concentrating on demonstrating haematopoiesis 
and engraftment. Detailed studies on the immune response comparing autologous 
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with allogeneic and maternal HLA-matched IUSCT will be necessary to study 
immune rejection of in utero transplanted cells. 
For clinical translation, demonstration that autologous IUSCT can cure 
congenital haematopoietic disease long term is required in a large animal model of 
disease. Our future work aims to test this in a haemophilia A sheep model [30]. 
Recent data in this model showed that postnatal transplantation with paternal MSCs 
transduced with a porcine FVIII-encoding lentivector and transplanted via the 
intraperitoneal route without preconditioning resulted in a phenotypic correction for 
up to a year after transplantation, but long-term cure was not possible due to the 
development of antibodies to the porcine FVIII protein [31]. The use of autologous 
cells and ovine FVIII may avoid this problem. The immune response and safety of 
IUSCT using transduced autologous AF cells for the fetus and mother will also need 
to be explored, and suitable vectors developed that produce regulated long term 
expression. Ultimately repeated postnatal infusion of transduced autologous AF cells 
may be required. Prenatal screening and diagnosis for haematological diseases 
such as thalassaemia and sickle cell already exists in many countries with the 
current aim of offering couples termination of pregnancy if an affected fetus is 
detected. Non-invasive prenatal diagnosis using circulating free fetal DNA from the 
mother’s blood is now a clinical reality for some congenital disease and will allow the 
earlier detection of fetuses affected with haematological disease. Autologous IUSCT 
with gene corrected cells may provide a treatment option. 
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Figure Legends 
Figure 1. Experimental design.  
Transduced sheep eGFP+ CD34+ selected fresh or frozen amniotic fluid (AF) and 
adult bone marrow (BM) cells were transplanted into immunocompromised NSG 
mice (primary and secondary xenogeneic transplantation). Transduced sheep 
eGFP+CD34+ fresh AF cells were also injected into donor sheep fetuses (in utero 
autologous transplantation) that were subsequently delivered and followed for up to 
3 months of age. Bone marrow from these primary sheep recipients was then used 
to perform xenogeneic secondary transplantation into NSG mice. 
Figure 2. Characteristics of sheep CD34+ cells from frozen and fresh AF, and from 
adult BM.  
(A) Proportion and (B) characteristics of CD34+ cells isolated from three sheep cell 
sources. There was no significant difference in the proportion of CD34+ cells isolated 
from the three cell sources. AF: amniotic fluid (frozen or fresh); BM: bone marrow. 
Error bar: standard deviation. (C) The morphology and percentage (D) of the three 
different types of haematopoietic colonies that grew in semi-solid culture of sheep 
CD34+ AF or adult BM cells. CFU-GEMM: colony forming unit-granulocyte, 
erythrocyte, monocyte, megakaryocyte; CFU-G/M/GM: colony forming unit-
granulocyte/monocyte/granulomonocyte; BFU/CFU-E: burst-forming unit/colony 
forming unit-erythroid. (E) Example of a flow cytometry study to characterise sheep 
CD34+ cells from fresh AF.   Cells are positive for CD45, but negative for CD14, 
CD31, CD44, and CD58. Red line: negative control, blue line: cells tested. (F) Flow 
cytometry showing eGFP+ cells 48 hours after lentivector (HIV.SFFV.eGFP) gene 
transfer to CD34+ sheep AF cells. X-axis: GFP channel, Y-axis: cell number count, 
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the number on the gate represents the percentage of eGFP+ positive cells out of 
total population. 
 
Figure 3. Analysis for engraftment of transduced sheep CD34+eGFP+ AF or adult 
BM cell sources in the peripheral blood and BM of primary transplanted NSG mice.  
(A) Peripheral blood engraftment. Left panel shows a representative flow cytometric 
dot plot of peripheral blood from NSG mice injected with frozen or fresh AF or adult 
BM cells respectively. The distinct population of cells in the upper right quadrant of 
each graph exhibit a positive signal for eGFP. X-axis: GFP channel, Y-axis: PE 
channel. The histogram (right panel) compares blood engraftment after injection of 
transduced CD34+eGFP+ sheep cells from the three sources (n=4, each group) at 1 
and 3 months after transplantation. There was significantly higher engraftment when 
the cell source was adult sheep BM (black bar) compared with cells sourced from 
frozen AF (light grey bar) or fresh AF (dark grey bar). Error bar: standard deviation; *: 
p<0.05; AF: amniotic fluid. Blood from YFP transgenic mice was used as a positive 
control while blood from uninjected NSG mice served as the negative control. (B) 
NSG mice BM engraftment. Left panel shows an example of flow cytometry to 
analyse engraftment of eGFP+ cells in the BM of primary NSG mouse recipients 
three months after transplantation. X-axis: eGFP+ cells, Y-axis: PE channel. The 
distinct population of cells in the upper right quadrant of each graph exhibit a positive 
signal for eGFP. Negative control: BM from uninjected mice; positive control: YFP 
transgenic mice. The histogram (right panel) compares the percentage of eGFP+ 
cells in the BM of primary NSG mouse recipients of transduced sheep CD34+eGFP+ 
cells from the three sources (n=4, each group) at 3 months after transplantation. 
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There was no significant difference in the percentage of engraftment in the BM. The 
BM cells from transgenic YFP mice were used as the positive control, and bone BM 
cells from uninjected mice were used for the negative control. Error bar: standard 
deviation. (C) Engrafted cells characteristics. The left panel shows the colony-
forming assay to study eGFP+ cells in the BM of primary mouse NSG recipients. 
Positive green colonies showing characteristics of all three major progenitor cell 
types could be detected. Positive control: BM from a YFP mouse, Negative control: 
BM from uninjected mice. Upper panel: phase contrast field; lower panel: green 
fluorescence signal. Bar: 100µm. Histogram (right panel) shows the percentage of 
eGFP+ colonies in the BM of primary NSG recipient mice three months after 
transplantation with transduced sheep CD34+ eGFP+ cells from three cell sources. 
BM from NSG mice transplanted with cells from adult sheep BM had a significantly 
higher percentage of eGFP positive colonies than the other two groups (*p<0.05, 
ANOVA). Error bar: standard deviation. 
 
Figure 4. Engraftment analysis of other organs of primary transplanted NSG mice. 
(A) The table shows PCR detection of eGFP+ DNA in the tissues of NSG mice 
transplanted with sheep CD34+eGFP+ cells. Eight out of 9 animals showed an 
eGFP+ signal in the liver, while 5 out of 9 and 2 out of 9 were positive in the spleen 
and adrenal gland respectively. Sheep-specific beta-actin was used for the internal 
control primer. (B) Analysis for engraftment in other haematopoietic tissues. The left 
panel shows the flow cytometry results. The bar in the graphs show the percentage 
of eGFP+ cells in tissues as presented by the small peak located to the right. The 
right panel shows the summary graphs. Cell sources were frozen AF (light grey), 
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fresh AF (dark grey) and adult BM (black). In the liver, there was a significantly lower 
percentage of eGFP+ cells after transplantation with the frozen AF cell source when 
compared to the other two cell sources. There was no difference in spleen 
engraftment. Error bar: standard deviation, *: p<0.05. (C) Confocal microscopy 
shows eGFP+ cells in the liver of transplanted NSG mice. Green: eGFP in the 
cytoplasm. Blue: DAPI for the nucleus. Bar: 10µm. (D) Immunofluorescence study on 
a liver section from an NSG mouse transplanted with fresh CD34+eGFP+ AF cells. 
In the liver, rare cells that co-stained with eGFP and alpha-fetoprotein (AFP) were 
found. Bar: 10µm. (E) Level of liver engraftment: eGFP+ cells per high power field 
(HPF) were counted by three individuals blinded to the study. There was no 
statistically significant difference between the groups (ANOVA). 
 
Figure 5. Analysis of NSG mice after secondary transplantation. 
(A) Flow cytometry analysis of the peripheral blood of secondary NSG mice 
recipients at 1, 2, and 3 months after transplantation. The bone marrow (BM) cell 
source group (NSG21, NSG22, blue lines) showed high r level of eGFP+ cells in the 
blood than the frozen amniotic fluid (AF; red lines) and fresh AF (green lines) cell 
source groups. No cells were detected in the blood of two animals injected with 
frozen or fresh AF (NSG16 and NSG20). Control: uninjected animal (grey line).  (B) 
Flow cytometry of the haematopoietic organs of NSG mice recipients showing the 
percentage of eGFP+ cells three months after secondary transplantation.  
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Figure 6. In utero autologous intraperitoneal transplantation of sheep amniotic fluid 
CD34+ cells in fetal sheep with long-term follow up.  
(A) Summary of fetal sheep experiments. Ultrasound-guided amniocentesis was 
used to collect 20ml of AF from each fetus, and CD34+ cells were selected. After 48 
hours of lentivector transduction in vitro the transduced CD34+AF-derived cells were 
injected back into the donor fetus by ultrasound-guided intraperitoneal injection. (B) 
Engraftment in the peripheral blood after in utero transplantation of autologous 
sheep CD34+eGFP+ AF cells. All five born lambs showed eGFP+ cells in the 
peripheral blood at birth, and all three survivors revealed persistent levels of 
engraftment of around 2% up to the last sampling point at 6 months of age. Negative 
control: peripheral blood from uninjected sheep. M3, M4 and M5: the three ewes that 
showed negativity for eGFP signal. 
 
Figure 7. Secondary xenogeneic transplantation of the BM cells from in utero 
autologous transplanted lambs into NSG mice.  
(A) Following in utero transplantation of transduced autologous sheep CD34+eGFP+ 
AF cells, lamb BM (n=3) was collected at 6 months of age and was confirmed to be 
positive for eGFP by flow cytometry. (B) These lamb BM samples were transplanted 
into secondary NSG recipients (xenogeneic transplantation) and flow cytometry of 
peripheral blood, liver and BM of these secondary recipients demonstrated eGFP+ 
cells. Negative control: uninjected lamb BM cells; Positive control: BM cells of YFP 
transgenic mice. (C) Summary table showing results of secondary 
xenotransplantation of BM from in utero transplanted lambs into NSG recipients. +: 
positive for eGFP band by PCR; -: negative for eGFP; n/a: not available. Positive 
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control: samples from YFP mice, Negative control: samples from un-injected NSG 
mouse. 
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